Recce Pharmaceuticals Advances Phase 3 Diabetic Foot Infection Trial Following Clean Indonesian Regulatory Inspection
Key Insights
Recce Pharmaceuticals (search) successfully completed a routine regulatory inspection by Indonesia's BPOM (search) for its Phase 3 diabetic foot infection trial, with no findings that would prevent the study from continuing.
The R327 G301 trial is progressing across five Indonesian sites with patient dosing ongoing and an interim analysis planned once 155 patients are completed.
Indonesia represents a significant commercial opportunity with over 20 million adults affected by diabetes (search), positioning the company for potential regulatory approval in 2026.
Recce Pharmaceuticals (search) has cleared a critical regulatory milestone in Indonesia, with the country's National Agency of Drug and Food Control (BPOM (search)) completing a routine inspection of the company's Phase 3 clinical trial site for diabetic foot infections (search) without identifying any issues that would impede the study's progress.
The inspection involved a comprehensive review of trial conduct, site processes, data integrity and compliance with Good Clinical Practice standards. According to the company, the clean outcome removes a layer of regulatory uncertainty at a crucial development stage and reinforces confidence in the study's integrity and broader approval pathway.
Phase 3 Trial Progress and Market Opportunity
The R327 G301 trial is currently advancing across five sites in Indonesia, with patient dosing ongoing and an interim analysis scheduled once 155 patients have been completed. Chief Executive James Graham characterized the inspection result as validation of the company's clinical execution and data quality standards.
"We are pleased with the outcome of BPOM (search)'s inspection, which reinforces the high standards of our clinical program maintained by our teams and partners working throughout Indonesia," Graham stated. "This result provides further confidence in the integrity of our data collection and the robustness of our development pathway as we progress towards potential regulatory approval."
The Indonesian market presents substantial commercial potential for Recce, with regulatory approval anticipated in calendar year 2026. The opportunity is underpinned by Indonesia's significant diabetes (search) burden, affecting more than 20 million adults and ranking among the highest prevalence markets globally. This creates a substantial addressable population for diabetic foot infections (search) and positions the company at the entry point to a broader Asia Pacific market estimated at approximately $1.5 billion.
Expanded Patent Protection in Brazil
Simultaneously, Recce has strengthened its intellectual property position by securing a Family 4 patent grant in Brazil, extending protection for its synthetic anti-infectives platform through 2041. The patent, awarded by Brazil's National Institute of Industrial Property (search), covers the company's lead compounds RECCE 327 (R327) and RECCE 529 (R529), including their manufacturing processes, therapeutic applications and multiple delivery methods.
This approval represents Recce's seventh granted patent in the Family 4 portfolio, joining existing jurisdictions including Australia, Canada, China, Hong Kong, Israel and Japan. The Brazilian patent provides comprehensive coverage across infectious disease applications, including acute bacterial skin and skin structure infections (search), diabetic foot infections (search), burn wounds (search), lung infections (search), urinary tract infections (search) and viral diseases such as influenza (search) and SARS-CoV-2 (search).
Strategic Market Entry
The patent grant positions Recce in one of the world's largest antibiotic markets, with Brazil's antibiotics sector generating approximately $774.5 million in revenue in 2024 and projected to reach roughly $964.3 million by 2033. The protection extends to multiple delivery formats including oral, inhalation, transdermal and injectable routes, as well as topical applications such as gels, foams and dressings.
"Patent protection is fundamental to Recce, and we are encouraged by the expansion of our patent portfolio into Brazil, South America's largest antibiotic market," Graham noted. "As we look to address the urgent and growing global burden of antibiotic-resistant superbugs, this granted patent is yet another intellectual property milestone."
Platform Technology and Pipeline
Recce's strategy centers on its synthetic anti-infective platform, with RECCE 327 being developed as both an intravenous and topical therapy targeting serious infections, including those involving antibiotic-resistant bacteria (search). The company's pipeline includes three core candidates: R327 for serious bacterial infections (search), R435 as an oral therapy, and R529 targeting viral infections (search).
The synthetic polymer approach is designed to overcome resistance mechanisms that limit traditional antibiotics, addressing the growing challenge of antibiotic-resistant superbugs. The latest developments build on Recce's ongoing clinical progress, including its Phase 3 diabetic foot infection trial and US Army-backed work on its RECCE 327 burn gel formulation.